Akums Drugs & Pharma
427.75
+8.25(+1.97%)
Market Cap₹6,732.53 Cr
PE Ratio20.54
IndustryHealthcare
Company Performance:
1D+1.97%
1M-6.44%
6M-25.80%
1Y-29.57%
5Y-46.28%
View Company Insightsright
More news about Akums Drugs & Pharma
22Aug 25
Akums Drugs Inks Framework Agreement with Zambia for Local Manufacturing Facility
Akums Drugs & Pharma signed a Framework Agreement with the Zambian government to set up a local manufacturing facility. The joint venture, with Akums holding 51% stake, aims to begin operations in 2028, producing various pharmaceutical products. Until then, Zambia will purchase medicines worth $50 million over two years from Akums' Indian facilities. The collaboration seeks to support Zambian health programs, enhance local production, and potentially export to neighboring African countries. Akums will provide technology and expertise through a separate agreement.
18Aug 25
Akums Drugs Reports 19% EBITDA Growth in Q1, Expands European Presence
Akums Drugs & Pharma, a leading CDMO, reported Q1 results with total income up 2.40% to Rs. 1,051.00 crores and EBITDA growth of 19% to Rs. 156.00 crores. EBITDA margin expanded by 208 basis points to 14.80%. The CDMO segment grew 4% despite API price impacts. Domestic and international branded formulations showed modest growth. The company made progress in European expansion, receiving approvals and certifications. R&D efforts yielded 27 DCGI approvals. Management expects mid-single digit growth for CDMO business with 14-15% margins and targets $100 million in formulation exports over five years.
08Aug 25
Akums Drugs Reports 19% YoY Growth in Adjusted EBITDA, Achieves 1,000 DCGI Approvals Milestone
Akums Drugs & Pharma, India's largest CDMO, reported robust Q1 results with total income of ₹1,051.00 crore and adjusted EBITDA of ₹156.00 crore, up 19.10% year-on-year. EBITDA margins improved to 14.80%. The company secured 1,000 DCGI approvals, enhancing its product portfolio. The CDMO business contributed 79.00% to turnover with a 14.70% EBITDA margin. Akums made progress in global expansion, receiving its first European dossier approval for Rivaroxaban and filing a dossier in Switzerland. The company maintains a positive outlook, focusing on strengthening its CDMO leadership and driving operational excellence.
27May 25
Akums Drugs Swings to Profit in Q4, Revenue Grows
Akums Drugs has reported a significant financial turnaround in Q4, posting a net profit of ₹148 million compared to a ₹413 million loss in the same quarter last year. The company's revenue increased by 11.76% year-on-year to ₹10.55 billion. Sequential growth was also strong, with Q4 profit up 127.69% from the previous quarter's ₹65 million.
26May 25
AKUMS DRUGS Achieves Remarkable Turnaround in Q4 Financial Performance
AKUMS DRUGS has reported a significant financial turnaround in Q4. EBITDA surged to ₹939.00 crore from ₹31.00 crore year-over-year. The company turned profitable with a net profit of ₹148.00 crore, compared to a loss of ₹413.00 crore in the previous year. Revenue increased to ₹10.55 billion from ₹9.44 billion. EBITDA margin improved to 8.90% from 0.33%, indicating enhanced operational efficiency.
Akums Drugs & Pharma
427.75
+8.25
(+1.97%)
1 Year Returns:-29.57%
Industry Peers
Sun Pharmaceutical
1,821.20
(+0.60%)
Divis Laboratories
6,486.00
(-0.07%)
Torrent Pharmaceuticals
3,717.60
(-0.34%)
Cipla
1,525.20
(0.0%)
Dr Reddys Laboratories
1,246.10
(-0.26%)
Lupin
2,087.90
(+0.80%)
Zydus Life Science
941.40
(+0.44%)
Mankind Pharma
2,250.00
(+0.03%)
Aurobindo Pharma
1,230.50
(-0.43%)
Alkem Laboratories
5,729.50
(+0.76%)